Oncotelic Therapeutics
United States · Biotechnology, Healthcare, Health Care
Oncotelic Therapeutics, Inc. is focused on developing innovative therapies for cancer treatment, primarily through the use of immunotherapy. The company's key products include novel therapeutic agents designed to enhance the immune response against tumor cells, with a particular emphasis on maximizing patient outcomes in oncology. Its operations are primarily based in the United States, with plans
Key facts
- Headquarters
- United States
- Employees
- 22
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (OTLC)
- Website
- mateon.com
- Company page
Recent activity at Oncotelic Therapeutics
- : Oncotelic Therapeutics
- : Oncotelic Therapeutics Enters Joint Development Agreement with TechForce Robotics
- : SEC 8-K (1.01): On March 31, 2026, Oncotelic Therapeutics, Inc. entered into a Joint Development, Manufacturing, and Licensing Agreement with TechForce Robotics, Inc. This material definitive agreement outlines the joint development and manufacturing of AI-enabled, GMP-compliant robotic systems intended for pharmaceutical and related manufacturing environments. The partnership aims to integrate TechForce's robotic hardware with Oncotelic's proprietary PDAOAI Platform, including a non-exclusive license of certain intellectual property. This strategic collaboration is expected to enhance capabilities in robotic systems within the drug manufacturing sector.
- : Oncotelic Therapeutics
- : SEC 8-K (1.01): On December 4, 2025, Oncotelic Therapeutics, Inc. entered into subscription agreements as part of a financing offering. The Company issued a total of 11 units to accredited investors, with each unit containing a note valued at $25,000, bearing 12% annual interest. The notes are structured to mature two years following the final closing of the offering and are convertible into up to 250,000 shares each. This financing initiative is part of a larger offering aimed at raising funds and enhancing the Company's operational capacity.
- : MATEON THERAPEUTICS INC
- : MATEON THERAPEUTICS INC
- : MATEON THERAPEUTICS INC
- : MATEON THERAPEUTICS INC
- : OncoTelic Inc.
Oncotelic Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Seed | $712K |
| Dec 2025 | Seed | $275K |
| Aug 2020 | Seed | $2.0M |
| May 2019 | Venture | $27.0M |
| May 2019 | Seed | $600K |
Leadership
- Vuong Trieu, Executive Officer, Director
- William Schwieterman, Director
- Vuong Trieu, Executive Officer, Director
- William Schwieterman, Director
- Vuong Trieu, Executive Officer, Director
- Bobby Jr., Director
- Donald Reynolds, Director
- Simon Pedder, Director
- David Chaplin, Executive Officer, Director
- William Schwieterman, Executive Officer, Director
- Vuong Trieu, Director
- Saran, Chief Business Officer
Verified email and direct lines for Oncotelic Therapeutics’s decision-makers are on Fundz. See plans
Oncotelic Therapeutics in the news
Companies similar to Oncotelic Therapeutics
- Ovid Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- BiomX · Biotechnology, Healthcare, Health Care, Therapeutics
- Tempest Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Galecto · Biotechnology, Healthcare, Health Care, Therapeutics
- Adial Pharmaceuticals · Biotechnology, Healthcare, Health Care, Therapeutics
About Oncotelic Therapeutics: questions and answers
What does Oncotelic Therapeutics do?
Oncotelic Therapeutics, Inc. is focused on developing innovative therapies for cancer treatment, primarily through the use of immunotherapy. The company's key products include novel therapeutic agents designed to enhance the immune response against tumor cells, with a particular emphasis on maximizing patient outcomes in oncology. Its operations are primarily based in the United States, with plans
Where is Oncotelic Therapeutics headquartered?
Oncotelic Therapeutics is headquartered in United States.
How many employees does Oncotelic Therapeutics have?
Oncotelic Therapeutics has about 22 employees.
Has Oncotelic Therapeutics raised funding?
Yes. Fundz has recorded 5 funding events for Oncotelic Therapeutics. The most recent, Seed of $712K, was in Jul 2026.
What is the latest news on Oncotelic Therapeutics?
On Jul 22, 2026, Oncotelic Therapeutics
Is Oncotelic Therapeutics a public company?
Yes. Oncotelic Therapeutics is publicly traded under the ticker OTLC.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy